| Immediate consequences of cigarette smoking: rapid formation of polycyclic aromatic hydrocarbon diol epoxides Y Zhong, SG Carmella, P Upadhyaya, JB Hochalter, D Rauch, A Oliver, ... Chemical research in toxicology 24 (2), 246-252, 2011 | 88 | 2011 |
| Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development J Wang, S Iyer, PJ Fielder, JD Davis, R Deng Biopharmaceutics & drug disposition 37 (2), 51-65, 2016 | 70 | 2016 |
| Metabolism of [D10] phenanthrene to tetraols in smokers for potential lung cancer susceptibility assessment: comparison of oral and inhalation routes of administration Y Zhong, J Wang, SG Carmella, JB Hochalter, D Rauch, A Oliver, ... Journal of Pharmacology and Experimental Therapeutics 338 (1), 353-361, 2011 | 32 | 2011 |
| Rolapitant absolute bioavailability and PET imaging studies in healthy adult volunteers X Wang, ZY Zhang, D Powers, J Wang, S Lu, V Kansra Clinical Pharmacology & Therapeutics 102 (2), 332-339, 2017 | 23 | 2017 |
| Bioequivalence of intravenous and oral rolapitant: results from a randomized, open‐label pivotal study X Wang, ZY Zhang, D Powers, J Wang, S Lu, S Arora, L Hughes, ... The Journal of Clinical Pharmacology 57 (12), 1600-1606, 2017 | 20 | 2017 |
| Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide … J Wang, ZY Zhang, S Lu, D Powers, V Kansra, X Wang Supportive Care in Cancer 27, 819-827, 2019 | 17 | 2019 |
| Effects of rolapitant administered intravenously or orally on the pharmacokinetics of digoxin (P‐glycoprotein substrate) and sulfasalazine (breast cancer resistance protein … X Wang, ZY Zhang, S Arora, L Hughes, J Wang, D Powers, J Christensen, ... The Journal of Clinical Pharmacology 58 (2), 202-211, 2018 | 16 | 2018 |
| Phenanthrene metabolism in smokers: use of a two-step diagnostic plot approach to identify subjects with extensive metabolic activation J Wang, Y Zhong, SG Carmella, JB Hochalter, D Rauch, A Oliver, ... Journal of Pharmacology and Experimental Therapeutics 342 (3), 750-760, 2012 | 16 | 2012 |
| Preparation and characterization of a novel polymorph of indiplon, Form α L Xu, J Wang, B Xiao, J Yang, Y Liu, R Huang Bioorganic & medicinal chemistry letters 22 (2), 963-968, 2012 | 12 | 2012 |
| Effects of rolapitant administered intravenously on the pharmacokinetics of a modified cooperstown cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan) in … X Wang, ZY Zhang, S Arora, J Wang, S Lu, D Powers, V Kansra The Journal of Clinical Pharmacology 58 (8), 1074-1083, 2018 | 8 | 2018 |
| Analytical techniques adopted in the research of drug polymorphism J WANG, R HUANG, B XIAO, J YANG Chinese Journal of Pharmaceutical Analysis 27 (3), 464-469, 2007 | 7 | 2007 |
| Pharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjects X Wang, ZY Zhang, J Wang, D Powers, S Arora, S Lu, V Kansra Clinical pharmacology in drug development 8 (2), 160-171, 2019 | 6 | 2019 |
| Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly (ADP-Ribose) polymerase (PARP)-1 and-2 inhibitor ZY Zhang, X Wang, J Wang, HS Pentikis, V Kansra Annals of Oncology 28, v344, 2017 | 6 | 2017 |
| Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects ZY Zhang, J Wang, V Kansra, X Wang Investigational New Drugs 37, 139-146, 2019 | 5 | 2019 |
| Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects X Wang, J Wang, S Arora, L Hughes, J Christensen, S Lu, ZY Zhang The Journal of Clinical Pharmacology 59 (4), 488-499, 2019 | 4 | 2019 |
| 1588 Population pharmacokinetics of rolapitant in patients with chemotherapy-induced nausea and vomiting X Wang, J Wang, V Kansra European Journal of Cancer 3 (51), S233-S234, 2015 | 4 | 2015 |
| Pharmacokinetics of rolapitant in patients with mild to moderate hepatic impairment J Wang, X Wang, ZY Zhang, S Arora, S Lu, V Kansra The Journal of Clinical Pharmacology 58 (5), 686-693, 2018 | 3 | 2018 |
| Abstract C63: Effects of rolapitant on the pharmacokinetics of digoxin and sulfasalazine in healthy subjects X Wang, ZY Zhang, S Arora, L Hughes, J Wang, S Lu, J Christensen, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), C63-C63, 2015 | 3 | 2015 |
| Biotransformation and disposition of niraparib, an investigational, selective human PARP-1 and PARP-2 antagonist, in vitro ZY Zhang, X Wang, S Lu, J Wang, S Agarwal, R Martell, V Kansra DRUG METABOLISM REVIEWS 48, 52-52, 2016 | 2 | 2016 |
| Absorption, metabolism, and excretion of rolapitant, a highly selective and long-acting NK-1 antagonist, in healthy volunteers ZY Zhang, X Wang, D Powers, S Lu, J Wang, J Christensen, V Kansra DRUG METABOLISM REVIEWS 48, 50-51, 2016 | 2 | 2016 |
